Lymphocyte proliferation is key to the regulation of the immune system. Cyclin D2 is the first cell cycle protein induced following stimulation through the T-cell receptor, the B-cell receptor or cytokines. The promoter of this cyclin integrates a diverse range of signals. Through investigating the regulation of this promoter by interleukin-2 and phosphatidylinositol 3-kinase, we have identified a role for the transcription factor CREB, cAMP response element-binding protein. Mutation of the CREB-binding site reduced cyclin D2 promoter activity 5-10-fold. CREB-1 is phosphorylated at serine 133, a critical site for activity, in both T cells and EpsteinBarr virus immortalized B cells. The introduction of an S133A mutant of CREB-1 reduces IL-2 induction of cyclin D2 promoter activity, demonstrating a role for this phosphorylation site in promoter activity. Two inhibitors of protein kinase A reduce lymphocyte proliferation and CREB-1 phosphorylation. This study demonstrates that the cyclin D2 promoter is capable of being regulated by PI3K and CREB and identifies CREB-1 and protein kinase A as potential targets for altering lymphocyte proliferation.
Introduction
Lymphocyte proliferation is an essential feature of the immune system. A key element of proliferation is the entry of cells into the cell cycle. Predictably, this is a tightly controlled process that follows an ordered progression of molecular events in which the D-type cyclins are key regulators (Sherr, 1996) . The D-type cyclins, along with their partner cyclin-dependant kinases (cdk), are the first cell cycle proteins observed to be induced in the process of lymphocyte cell cycle entry. At the same time, the cyclin-dependent kinase inhibitors (CDKI), such as p27kip1, are downregulated. This permits the formation of catalytically active complexes comprising a cdk and a D-type cyclin whose activity facilitates the release of members of the E2F family of transcription factors from repressor pocket protein complexes. Through facilitating the induction of E2F transcriptional activity, expression of the D-type cyclins is a key factor in the regulatory processes governing progression through the G1 phase of the cell cycle.
Of the three D-type cyclins, only cyclin D2 and cyclin D3 are expressed in lymphocytes (Ajchenbaum et al., 1993; Palmero et al., 1993) . Cyclin D2 is the first to be induced in T cells and B cells during cell activation in response to a diverse range of cell stimuli, including receptor activation, costimulation and cytokines, such as interleukin-2 (IL-2) and interleukin-7 (Appleman et al., 2000; Lam et al., 2000; Martino et al., 2001) .
Phosphatidylinositol 3-kinase (PI3K) has been directly implicated in the regulation of D-type cyclins in T-lymphocytes (Brennan et al., 1997) ; however, the mechanism is still unclear. The transcription factor STAT5 has also been implicated in regulating cyclin D2. T cells from mice deficient in both STAT5a and STAT5b lose the ability to induce D-type cyclins, but retain the ability to downregulate p27kip1 (Moriggl et al., 1999) . STAT5 has been shown to bind directly to the cyclin D2 promoter. The constitutive transcription factor SP1 has also been shown to play a role in the regulation of the cyclin D2 promoter (Martino et al., 2001) .
Cyclin D2 regulation in B cells has some clear parallels with T cells. Cyclin D2 is induced by B-cell antigen receptor and cytokines (Solvason et al., 2000; Banerji et al., 2001) . PI3K is required for maximal induction of the protein (Banerji et al., 2001) . Following infection of B cells by the Epstein-Barr virus (EBV), cyclin D2 is the first cell cycle protein to be induced while at the same time the expression of the cdk inhibitor, p27kip1, is downregulated (Sinclair et al., 1994) . These observations imply that the virus exploits the host cell's signalling pathways to bring about transformation. Two viral genes, EBNA 2A and EBNA-LP, have been found to be sufficient to induce the expression of cyclin D2 (Sinclair et al., 1994) . EBNA 2A alone has been shown to be capable of indirectly transactivating the cyclin D2 promoter (Spender et al., 2001) . Inhibition of PI3K in EBV-immortalized B cells causes a downregulation of cyclin D2 (Brennan et al., 2002) .
This study was initiated to expand our understanding of the molecular events involved in the regulation of cyclin D2 in lymphocytes with a view to identifying molecular targets for the manipulation of lymphocyte growth. We have shown that PI3K is capable of directly activating the cyclin D2 promoter. Using promoter deletion constructs and electrophoretic mobility shift assay, we have identified a binding site for cAMP response element-binding protein-1 (CREB-1) in the cyclin D2 promoter. CREB-1 phosphorylation is important for promoter activity and is observed in both T cells and EBV-immortalized B -cells, where it appears refractory to PI3K inhibition. CREB-1 phosphorylation and lymphocyte proliferation were inhibited by two protein kinase A (PKA) inhibitors. These observations show that the cyclin D2 promoter can integrate signals from CREB-1 and PI3K and identify CREB-1 and PKA as potential targets for altering lymphocyte proliferation.
Results
Cyclin D2 protein and the cyclin D2 promoter is regulated by PI3K Cyclin D2 is a tightly regulated protein that is induced as lymphocytes enter the cell cycle. We have previously demonstrated that PI3K activity is required for the maximal induction of D-type cyclins in T cells and EBVimmortalized B cells (Brennan et al., 1997; Brennan et al., 2002) . Data from primary T cells is illustrated in Figure 1 . Primary T cells were partially purified from human blood, stimulated with phytohaemaglutinnin and IL-2 for a week. The cells were then quiesced for 48 h by removal of IL-2. They were either untreated or pretreated with LY294002, an inhibitor of PI3K (Vlahos et al., 1994) , for 30 min, prior to restimulation with IL-2 for 3 h (Figure 1a) . The result shows that cyclin D2 expression is reduced, not completely blocked, by Figure 1 IL-2 and PI3K regulate the cyclin D2 promoter. (a) Protein extracts were generated from quiesced human bloodderived T-cellsblasts following treatments as indicated. Proteins were resolved by SDS-PAGE, Western blotted and were measured by antibodies as indicated. (b) Kit225, an IL-2-dependent human T-cell line, was transfected with a reporter construct comprised of the human cyclin D2 promoter upstream of luciferase in the presence of empty vector and left unstimulated or stimulated with IL-2 (20 ng/ml) or cotransfected with an expression vector for CD2p110, an active mutant of PI3K (15 mg). Luciferase was measured at various times after transfection. (c) The extracts generated for luciferse assay were run on SDS-PAGE, Western blotted and analysed for CD2p110 expression using an anti-CD2 antibody (OX34). (d) Kit225 cells were transfected with a reporter construct comprised of the human cyclin D2 promoter upstream of luciferase in the presence of empty vector (20 mg), an expression vector for CD2p110 (20 mg) or a kinase dead mutant, CD2p110KD (20 mg), and left unstimulated or stimulated with IL-2. Cells were harvested 18 h after transfection and luciferase was measured. (e) Kit225 cells were transfected with a reporter construct comprised of the human cyclin D2 promoter upstream of luciferase, pretreated with LY294002 for 30 min and then IL-2 for 4 h. Results are the mean from two experiments, normalized to the luciferase measured from cells treated with IL-2.
LY294002. The cdk inhibitor p27kip1 does not change dramatically over this time scale (not shown). Actin is included as a loading control.
Having demonstrated the regulation of cyclin D2 by PI3K, we chose to investigate the ability of IL-2 and PI3K to regulate a reporter plasmid containing the cyclin D2 promoter. The reporter plasmid was transiently introduced into the IL-2-dependent T-cell line, Kit225, which had been cultured in the absence of IL-2 for 24 h prior to the transfection. Figure 1b shows the results of a time course of Kit225 cells transfected with the reporter plasmid and either stimulated with IL-2 (circles), cotransfected with an active mutant of the catalytic subunit of PI3K (CD2p110) (triangles) or left unstimulated (squares). A rapid, but transient, induction of cyclin D2 promoter activity was observed upon the application of IL-2. A more delayed but sustained induction of cyclin D2 promoter activity was seen by cotransfection of CD2p110. This delayed induction reflects the time required for CD2p110 expression, as illustrated in Figure 1c . The requirement for PI3K activity is demonstrated by the use of a kinase defective version of CD2p110 (CD2p110KD). While the active mutant of PI3K can induce cyclin D2 promoter activity, CD2p110KD does not have as dramatic an effect on the promoter (Figure 1d ). Cells were left overnight to allow expression from the cotransfected plasmid, so IL-2 had little effect at this time point. The induction of the cyclin D2 promoter by IL-2 was reduced by 60% by LY294002 (Figure 1e) showing a role for PI3K in the regulation of the promoter by IL-2.
Identification of a transcription factor-binding region in the cyclin D2 promoter. To identify the region of the cyclin D2 promoter that was subject to regulation by IL-2 and PI3K, a series of promoter deletion constructs (schematic shown in Figure 2a ) were used. Reporter plasmids containing these deletion constructs were transiently transfected into Kit225 cells, which were stimulated by the addition of IL-2 or the cotransfection of active PI3K (CD2p110). Progressive deletion of the promoter (schematic in Figure 2a ) caused a corresponding decrease in promoter activity (Figure 2b ). However, the most substantial loss of activity correlated with the loss of the region from À306 to À114 bp. This suggests Figure 2 Localization of an important protein-binding region of the cyclin D2 promoter. (a) Schematic of the cyclin D2 promoter. (b) Kit225, an IL-2-dependent human T-cell line, was transfected with deletion constructs of the cyclin D2 reporter, together with empty vector, and left unstimulated (white bars) or stimulated with IL-2 (20 ng/ml) (black bars) or cotransfected with an expression vector for CD2p110, an active mutant of PI3K (15 mg). The samples transfected with empty vector, with and without IL-2, were harvested 3 h after transfection, while the samples transfected with CD2p110 were harvested 18 h after transfection. These data are the results from a single experiment and are representative of four independent experiments. (c) Oligonucleotides corresponding to the cyclin D2 promoter were radiolabelled and incubated with nuclear extracts from unstimulated or IL-2-stimulated quiesced human blood-derived T-cell blasts. At least three protein-DNA complexes can be seen binding to the 320-270 bp region of the cyclin D2 promoter. This experiment was performed more than four times and similar results were seen from nuclear extracts of Kit225 cells. (d) Nuclear extracts from Kit225 cells were incubated with 10-fold excess unlabelled oligonucleotide, as indicated, in the presence of labelled oligonucleotide corresponding to À320 to À270 bp. Similar results were seen in two other experiments. that a transcription factor binding to this region is capable of regulating the basal cyclin D2 promoter activity as well as its induction in response to IL2 and PI3K.
We refined the region of the cyclin D2 promoter that was binding a transcription factor using electrophoretic mobility shift assays. A series of double-stranded oligonucleotide probes were generated whose sequences corresponded to this important part of the cyclin D2 promoter. Six oligonucleotide probes, each one 50 bp in length and incorporating a 10 base pair overlap, were generated to span the region from À360 to À110 bp. The probes were radiolabelled and used in electrophoretic mobility shift assays to identify a region of the promoter that was associated with DNA-binding factors. Nuclear extracts of human peripheral blood lymphocytes and Kit225 cells were probed. Figure 2c shows data from nuclear extracts of human peripheral blood lymphocytes stimulated with IL-2. Similar data were generated using Kit225 cells. All of the probes bound at least one protein complex from the nuclear extracts (marked with a white arrow). This complex demonstrated a relatively rapid electrophoretic mobility. However, the probe corresponding to the region of the cyclin D2 promoter between À320 and À270 bp was seen to bind to two additional protein complexes with slower electrophoretic mobility (dark arrows).
The specificity of the complexes binding to the oligonucleotide corresponding to À320 and À270 bp of the cyclin D2 promoter was assessed by competition with unlabelled versions of each probe ( Figure 2d ). The band demonstrating rapid electrophoretic mobility (white arrow) was lost by incubation with any of the unlabelled probes. However, only the application of same unlabelled probe resulted in the disappearance of the slower migrating complexes (dark arrows). This suggested that the two slower migrating bands represented specific DNA-binding complexes. None of the binding complexes underwent significant changes in the amounts of protein-DNA complexes detected upon treatment of the cells with interleukin-2 (Figure 2c) or LY294002 (not shown), indicating that the DNAbinding activity of the transcription factor is not modulated by IL2 induction.
CREB-1 binds to the cyclin D2 oligonucleotides in T cells and EBV-immortalized B cells
We identified the protein-DNA complex using a supershift assay. Antibodies directed against CREB-1 were chosen since the cyclin D2 promoter contains a putative binding site for CREB-1 located between À320 and À270 bp. Furthermore, CREB-1 has been shown to be regulated by long-term treatment of cells with IL-2 (Feuerstein et al., 1995a, b) . The effects on the putative CREB oligonucleotide derived from the cyclin D2 promoter were compared to a radiolabelled CREB-1 consensus sequence. Antibodies specific to either CREB-1 or CREB-2 were preincubated with nuclear extracts derived from Kit225 cells. Radiolabelled cyclin D2 probe or a radiolabelled probe corresponding to a consensus sequence of the CREB-1-binding site was then added. Figure 3a shows the results obtained from these supershift experiments. In the case of both probes, a comparison of the second lane and the third lane with the first lane shows a change in the DNA binding and a clear reduction of the electrophoretic mobility that is characteristic of an antibody-protein-DNA complex. The extracts in the second and third lane were incubated with two different CREB-1 antibodies and demonstrate Figure 3 CREB-1, from lymphocyte nuclear extracts, binds to an oligonucleotide from the cyclin D2 promoter. Supershift analysis of the À320 to À270 bp region of the cyclin D2 promoter using CREB-1 and CREB-2 antibodies. Nuclear extracts from (a) IL-2 stimulated Kit225 or (b) EPV-immortalized B cells were untreated (lanes 1 and 6) or incubated with specific antibodies raised to CREB-1 (lanes 2, 3, 7 and 8) or CREB-2 (lanes 4, 5, 9 and 10). The different lanes marked CREB1 and CREB2 represent incubation with two different antibodies. They were then incubated with an oligonucleotide corresponding to the À320 to À270 bp region of the cyclin D2 promoter (lanes 1-5) or a CREB-1 consensus oligonucleotide (lanes 6-10). This figure is representative of four experiments. (c) A DNA affinity precipitation was performed using nuclear extracts from EPV-immortalized B cells with oligonucleotides corresponding to consensus STAT, NF-kB or CREB oligonucleotides, as indicated or with an oligonucleotide corresponding to the À320 to À270 bp region of the cyclin D2 promoter. NE designates nuclear extract on which no precipitation has been performed. The precipitated proteins were separated by SDS-PAGE followed by Western blotting. CREB-1 was detected using a specific antibody.
that CREB-1 is a component of the complex. Two different CREB-2-specific antibodies were also tested (fourth and fifth lanes), but no effect was seen. This identifies CREB-1 as a transcription factor that binds to oligonucleotides that correspond to critical sections of the cyclin D2 promoter.
An electrophoretic mobility assay was performed with nuclear extracts from EBV-immortalized B cells to investigate if these cells contained CREB-1 capable of binding to the cyclin D2 promoter. Figure 3b shows that the pattern of DNA binding generated from EBVimmortalized B cells is almost identical to that obtained from T cells (Figure 3a) . The supershift experiments show that CREB1 from these nuclear extracts, but not CREB2, can bind to an oligonucleotide from the cyclin D2 promoter. The electrophoretic mobility shift assay was complemented by the precipitation of protein-DNA-binding complexes with biotinylated DNA. This DNA affinity precipitation technique was performed with nuclear extracts from EBV-immortalized B cells. The same nuclear extract was divided into five parts and incubated with streptavidin agarose beads in the absence of oligo (first lane, Figure 3c ), or in the presence of four different oligonucleotides. The oligonucleotides were consensus sequences corresponding to a STAT-binding sequence, an NF-kB-binding sequence or a CREBbinding sequence as well as the same 50 bp oligonucleotide from the cyclin D2 promoter used for the electrophoretic mobility shift assays. The proteins binding to the DNA were eluted into gel sample buffer, resolved by gel electrophoresis followed by Western blotting and antibody detection. Figure 3c shows that a large amount of CREB-1 can be precipitated with a CREB consensus oligonucleotide or the oligonucleotide from the cyclin D2 promoter, but that beads alone or beads with the STAT or NF-kB oligonucleotide do not precipitate much CREB1. A similar sized band is detectable in the nuclear extract (NE) in the absence of DNA precipitation. These two techniques indicate that the cyclin D2 promoter contains a binding site for CREB-1.
Phosphorylation at serine 133 of CREB-1 is important for cyclin D2 transactivation but is refractory to PI3K inhibition We investigated the importance of CREB-1 for the regulation of the cyclin D2 promoter, using a phosphorylation mutant of CREB-1 in which the critical serine residue at position 133 is converted to an alanine residue (S133A) (Mayr and Montminy, 2001 ). This mutant prevents the recruitment of the basal transcription machinery and inhibits CREB-1 transactivation. Transfection of mutant transcription factors can have strong effects on general cellular metabolism. For CREB, this was controlled for by transfecting Kit225 cells with the cyclin D2 promoter and with a reporter construct expressing Renilla luciferase under the control of SV40 early enhancer/promoter together with the wild-type or S133A CREB mutant. The relative lucifease was calculated and the ability of IL-2 to induce the promoter was investigated. IL-2 induced almost a sixfold increase in cyclin D2 promoter activity (Figure 4a ). Cotransfection of plasmids for both WT CREB and S133A CREB reduced cyclin D2 activity induced by IL-2 compared to that observed in the presence of empty vector alone. The S133A CREB expressing plasmid reduced cyclin D2 promoter activity more significantly than WT CREB (Po0.01). The expression of CREB was measured and neither WT CREB nor S133A CREB caused a dramatic increase in expression (data not shown).
It was important to demonstrate that CREB-1 was phosphorylated at position 133 in lymphocytes as phosphorylation alters the ability of CREB-1 to transactivate genes (Mayr and Montminy, 2001 ). This was investigated in both T cells and EBV-immortalized B cells following treatment with LY294002, the PI3K inhibitor. Nuclear extracts were generated and were resolved on SDS-polyacrylamide gel electrophoresis (PAGE) followed by Western blotting and antibody detection utilizing a phosphospecific antibody directed against the amino-acid sequence flanking the critical serine residue at position 133 of CREB. Figure 4b and c presents the results from a representative experiment utilizing Kit225 cells and EBV-immortalized B cells, respectively. It demonstrates that the phosphorylation of CREB-1 at serine 133 was constitutive in these cells, and that it was refractory to the inhibition of PI3K. The effectiveness of LY294002 to inhibit PI3K was shown by inhibition of S6 phosphorylation in response to IL-2 (Figure 4b ). CREB-1 phosphorylation was also investigated in EBV-immortalized B cells. Similar to the data observed in T cells, CREB-1 phosphorylation was constitutive and refractory to treatment of the cells with LY294002, while S6 phosphorylation was inhibited by treatment of the cells with LY294002 (Figure 4c ).
DNA affinity precipitation was used to investigate whether CREB-1 that was capable of binding DNA was phosphorylated. Figure 4d shows CREB-1 precipitated from Kit225 cells with an oligonucleotide corresponding to the cyclin D2 promoter. In all cases, phosphorylated CREB-1 has been precipitated with DNA, indicating that phosphorylated CREB-1 is capable of binding to the oligonucleotide corresponding to the cyclin D2 promoter.
The CREB-1 site in the cyclin D2 promoter is required for promoter activity in T cells and EBV-immortalized B cells The significance of having an intact CREB-1-binding site in the cyclin D2 promoter was investigated by the generation of altered versions of the promoter in which the CREB-1-binding site was mutated by PCR (illustrated in schematic, Figure 5a ). Two versions of the promoter containing the mutated CREB-1-binding site were made, one truncated at À1303 bp and the other at À444 bp. This allowed us to investigate the effect of the loss of the CREB-binding site in a more full-length form of the promoter as well as a reduced promoter. These altered promoters, along with their unmutated counterparts, were introduced into the pGL3 luciferase reporter plasmid. Each of the four plasmids was separately transfected into Kit225 cells at two doses, 5 and 10 mg. Figure 5b shows the decrease in reporter activity observed in promoters lacking the CREB-1-binding site. The EBV-immortalized B-cell line (IB4) was transfected with a single dose of the À1303 bp cyclin D2 reporter plasmid or the promoter containing the mutations in the CREB-1 site. There is a dramatic loss in promoter activity in the absence of a functional CREB-1-binding site (Figure 5c ).
KT5720, a protein kinase A inhibitor, prevents CREB phosphorylation and proliferation of lymphoblastoid cells
To investigate the kinase that regulates the phosphorylation of CREB at serine 133, we used a selection of protein kinase inhibitors (supplied as a set by Calbiochem). These inhibitors targeted a range of kinases, some of which have been implicated in the regulation of CREB phosphorylation. The inhibitors were Ro-31-8220, a PKC inhibitor; Genistein, a broad spectrum Figure 4 CREB-1 is phosphorylated and its phosphorylation and binding are important for cyclin D2 promoter activity. (a) Kit225 cells were cotransfected with the human D2 promoter and phRL-SV40 together with various amounts of an expression vector for CREB-1 or S133A CREB-1. The amount of DNA was kept constant by the addition of empty vector (pcDNA3). Cells were stimulated with IL-2 for 18 h. Data were normalized using the Renilla luciferase and is expressed as a fold activation induced by IL-2. Error bars represent the mean and standard error of the mean from three independent experiments. (b) Protein extracts were generated from Kit225 cells that had been pretreated with LY294002 for 30 min, stimulated with IL-2 for 1 h. Protein extracts were analysed by SDS-PAGE, and probed with specific antibodies as indicated. (c) To investigate the phosphorylation status of DNA bound CREB-1, a DNA affinity precipitation was performed on Kit225 cell nuclear extracts, with an oligonucleotide corresponding to the À320 to À270 bp region of the cyclin D2 promoter. The precipitated proteins were resolved by SDS-PAGE followed by Western blotting and detection with specific antibodies. (d) Lymphoblastoid cells were treated with various doses of LY294002 as indicated for 1 h. Protein extracts were generated and analysed as in (b) . Representative experiments are shown from at least four experiments. tyrosine kinase inhibitor; KN-93, an inhibitor of Cam kinase II; KT5720, an inhibitor of protein kinase A (PKA), staurosporine, an broad spectrum serine/threonine kinase inhibitor and U0126, an inhibitor of MEK1 and MEK2. EBV-immortalized B cells (IB4) were treated with each of these agents for 1 h. Nuclear extracts were generated, resolved by SDS-PAGE followed by Western blotting. The phosphorylation of CREB was analysed using a specific antibody followed by analysis of total CREB and actin (Figure 6a ). Both staurosporine, the broad spectrum inhibitor, and KT5720, a PKA inhibitor, reduced the amount of CREB serine 133 phosphorylation that could be detected. KT5720 also reduced the amount of total CREB detected. Figure 5 Loss of the CREB-1-binding site in the cyclin D2 promoter activity causes a dramatic loss of activity. Two doses of each of the four cyclin D2 promoters, two of which contained a mutation within the CREB-1-binding site (illustrated in schematic (a)), were transfected into Kit225 cells. After 4 h, cells were lysed and luciferase activity was determined (b). IB4 lymphoblastoid cells were transiently transfected with the full-length cyclin D2 promoter and the promoter containing a mutation in the CREB-1 site after 16 h (c). A range of concentrations of both staurosporine and KT5720 was used (Figure 6b ). The inhibition of CREB phosphorylation was dose responsive. IB4 LCL were treated with staurosporine for 24 h to investigate the effect on cell proliferation. However, staurosporine caused cell death within 24 h, making an investigation of proliferation impossible. IB4 LCL were treated with various doses of KT5720 to investigate cell proliferation. KT5720 did not cause cell death but did result in an inhibition of cell proliferation, which correlated with the inhibition of CREB serine 133 phosphorylation (Figure 6c) .
Two PKA inhibitors, KT5720 and H-89, reduce Kit225 cell proliferation KT5720, and a structurally distinct PKA inhibitor, H-89, were tested on Kit225 cells, the IL-2-dependent Tcell line. The Kit225 cells were washed out of IL-2 for 72 h. They were then pretreated with various concentrations of both inhibitors prior to the addition of IL-2. Samples were taken for protein analysis after 24 h and cell number and viability were assayed after 48 and 72 h. The analysis of cell number showed that IL-2 caused an increase in the number of cells present at 48 and 72 h and this increase was reduced in the presence of both KT5720 and H-89 (Figure 7a and b) . U0126, (500 nM), which did not alter CREB phosphorylation, does not significantly inhibit proliferation (data not shown). The effect of four doses of each inhibitor, after 72 h, was calculated as a percentage of IL-2 alone, for the number of cells (Prolif) and the percentage of cells alive (Alive). Cell viability was reduced in cells treated with H-89 but in the case of both inhibitors, there was a clear difference in the concentrations that reduce cell proliferation and affect cell survival. Both inhibitors also reduced entry into S phase of the cell cycle after 24 h (not shown). CREB phosphorylation at Serine 133, CREB, cyclin D2 and actin expression were also measured after 24 h. Both KT5720 and H-89 reduced CREB phosphorylation and cyclin D2 expression (Figure 7c and d) compared to that observed in cells treated with IL-2 alone. Whereas the doses of the inhibitors required to reduce phosphorylation of CREB correlated with those required for proliferation, the concentrations required to reduce cyclin D2 expression were higher. This suggests that while PKA seems to play a key role in the regulation of lymphocyte proliferation, through CREB phosphorylation, the cyclin D2 gene is likely to be the only one mechanism by which this might occur.
Discussion
This study has focused on the cyclin D2 promoter as a way of increasing our knowledge of lymphocyte proliferation. We have shown that PI3K can regulate the cyclin D2 promoter. Our work has identified a CREB-binding site, located À290 bp upstream of the translation start site using both promoter reporter assays and electrophoretic mobility shift assays. Most interestingly, two PKA inhibitors have been shown to reduce lymphoctye proliferation suggesting that PKA and CREB are important for the regulation of lymphocyte proliferation.
Our work suggests that CREB-1, directly, and PI3K indirectly can regulate the cyclin D2 promoter. In T cells, STAT5 and SP1 have been shown to bind to a region at À1204 bp upstream (Martino et al., 2001) . IL-2 is a strong regulator of both STAT5 and PI3K. The critical role for STAT5 is shown by the loss of cyclin D2 in STAT5-deficient mice (Moriggl et al., 1999) . Both STAT5 and PI3K appear to signal independently which probably explains why PI3K only reduces rather than blocks cyclin D2 expression. The effect of two inhibitors of PKA indicates that PKA plays an important role in CREB serine 133 phosphorylation. IL-2 appears to cause an increase in CREB serine 133 phosphorylation, which is inhibited by KT5720. However, it is possible that PKA activity may be a prerequisite for this phosphorylation rather than being directly regulated by IL-2. KT5720 reduces the total level of CREB-1, suggesting a role in protein expression. Interestingly, KT5720, H-89 and staurosporine also inhibited the phosphorylation of a lower molecular weight band detected using the phosphoCREB antibody. This may be ATF-1 although we have not demonstrated this with specific antibodies. CREB-1 and ATF-1 can heterodimerize so the activity of ATF-1 may play a role in the regulation of CREB-1 and cyclin D2. The regulation by IL-2 and interplay between CREB-1 and ATF-1 is currently under investigation in our laboratory.
Our work adds weight to a body of data demonstrating that the cyclin D2 promoter can integrate the activity of many molecules within the cell. The oncogene product Tax of human T-cell leukaemia virus type I can regulate the cyclin D2 promoter through the CRE site that we have identified as binding CREB, and through an NF-kB site located at À130 bp upstream of the ATG site (Huang et al., 2001) . It has been reported that the cyclin D2 promoter is repressed by a Mad-Max complex that binds to an E-box at À1200 bp in NIH 3T3 cells. A number of other molecules also appear to regulate the cyclin D2 promoter indirectly. These include the EPV gene, EBNA2A (Spender et al., 2001) , transcription factors of the FoxO family (Schmidt et al., 2002 ) and Bruton's tyrosine kinase (Fruman et al., 2002) . Thus, the cyclin D2 promoter appears to be directly regulated by at least five different transcription factors, and indirectly by other pathways. The hierarchy of these different molecules remains to be elucidated, but our data suggest that the CREB-1-binding site is important.
There is accumulating evidence demonstrating that CREB-1 can regulate the proliferation of T cells. A transgenic mouse expressing a dominant negative CREB-1 showed defective thymocyte proliferation (Barton et al., 1996) . Mice deficient in CREB-1 lose alpha beta T-cell development (Rudolph et al., 1998) . CREB-1 has also been implicated in regulating another cell cycle gene, proliferating cell nuclear antigen (Belkowski et al., 1998) . There is also a correlation between molecules that have been reported to induce CREB-1 and lymphocyte proliferation. These include the maximal induction of CREB-1 phosphorylation by CD3/ CD28 costimulation (Yu et al., 2001) in T cells. This treatment causes robust proliferation and an induction of cyclin D2. CREB-1 has also been implicated in the proliferative responses of B cells. Similar to T cells, transgenic expression of dominant negative CREB-1 impaired proliferation of B cells (Zhang et al., 2002) . CREB-1 phosphorylation is regulated by the B-cell receptor, an essential step in the induction of proliferation (Xie and Rothstein, 1995) . Interestingly, IFNgamma-mediated inhibition of antigen receptor-induced B-cell proliferation correlated with a loss of CREB-1 phosphorylation (Frissora et al., 2003) . Thus, our data demonstrating that CREB-1 can bind and regulate the cyclin D2 promoter help to provide a molecular mechanism for many of these observations. The ability of KT5720 and H-89 to inhibit lymphocyte proliferation raises the possibility that PKA, CREB-1 or cyclin D2 could be therapeutic targets. As CREB-1 is elevated in both T cells and B cells, it is possible that it could be a valuable target for the treatments of lymphoma, or to manipulate lymphocyte proliferation for other conditions such as in rheumatoid arthritis and transplantation, although its role in other cell types may limit this. Diffuse large cell lymphomas and Hodgkin's lymphomas have been shown to express cyclin D2 (Teramoto et al., 1999) . Cyclin D2 induction by the T-cell oncogenic virus, HTLV-1, and the B-cell virus, EBV, both require CREB-1 binding (Huang et al., 2001 ; and this study). Furthermore, cyclin D2 expression is a feature of chronic lymphocytic leukaemia (Delmer et al., 1995) and identifies poor-risk gastric cancers (Takano et al., 1999) . One study from CML cells places cyclin D2 downstream from the BCR-ABL translocation. If CREB-1 can regulate cyclin D2 in these various other cancers, targeting CREB-1 or cyclin D2 directly may be useful. For PKA, an inhibitor is available, but roles for PKA and CREB-1 in long-term potentiation and memory situations makes targeting these molecules more challenging (Mayr and Montminy, 2001; Waltereit and Weller, 2003) . However, we have shown, in another study, that combinations of low doses of pharmacological agents can inhibit lymphocyte proliferation (Breslin et al., 2005) . It is conceivable that reducing PKA, CREB-1 or cyclin D2 by a small amount may have therapeutic benefit, particularly in combination with other agents.
Materials and methods

Cell culture
Kit225 cells (Hori et al., 1987) , a human IL-2-dependent T-cell line, were maintained in RPMI media supplemented with 20 ng/ml IL-2 (Chiron, UK) in a 5% CO 2 humidified incubator. In the absence of IL-2, these cells accumulate in the G1 phase of the cell cycle. The cells were deprived of IL-2 for 48 h prior to transfection by washing the cells twice in RPMI media. For other experiments, the cells were deprived of IL-2 for 72 h. IL-2 receptor expressing human peripheral blood-derived T lymphoblasts were generated and maintained as described previously (Beadling et al., 1994) . The cells were quiesced by washing three times in RPMI, and replaced in RPMI 1640 with 10% serum in the absence of IL-2 for 48-72 h. All lymphoblastoid cell lines including IB4 LCL, an LCL generated from cord blood B cells (Sample and Kieff, 1990) , were immortalized by B95.8 virus and were maintained in RPMI medium.
Western blotting and antibody detection Samples for Western blots were generated in three different ways. For Western blotting analysis performed in parallel with reporter assays, cells were washed in phosphate-buffered saline and lysed for 30 min on ice in luciferase lysis buffer. The lysates were clarified by centrifugation at 13 000 g for 5 min, and the soluble fraction was then added to an equal volume of 2 Â gel sample buffer (0.1 M Tris buffer pH 6.8, 0.2 M dithiothreitol, 4% sodium dodecyle sulphate, 20% glycerol, 0.1% bromophenol blue) and boiled for 2 min. Total lysates were generated by resuspending cells in PBS and lysis in an equal volume of 2 Â gel sample buffer. Nuclear and cytosolic extracts were also used for SDS-PAGE and Western blotting as described below.
Proteins were separated by SDS-PAGE and transferred to PVDF membranes for immunoblotting using an alkaline phosphatase chemiluminescent detection protocol (Mehl et al., 2001) . Antibodies to cyclin D2 (sc-593) and p27 (sc-1641) were from Santa Cruz Biotechnology and were used at a concentration of 200 ng/ml). Antibodies to phospho CREB Ser 133 (x9191), pan CREB (x9192), phospho S6 Ser 235/236 (x2211) and pan S6 (x9611) were from Cell Signaling Technologies and were used at a 1/1000 dilution of the stock supplied. The antibody to actin (A-2066) was from Sigma and was used at a 1/1000 dilution of the stock supplied. The antibody to rat CD2 (OX34), a mouse monoclonal, was from Cancer Research UK.
Plasmids
The cyclin D2 promoter plasmids and the promoter deletions were provided by Dr Dov Shiffman (Brooks et al., 1996) . Two further human cyclin D2 promoter constructs (À1303 and À444) and the CREB-binding mutants were generated in pGL3 from the wild-type pGL2 human cyclin D2 promoters (À1303 and À444) used previously through subcloning the respective promoter regions into the pGL3-basic vector (Promega, UK). The wild-type human cyclin D2 promoter was then mutated to introduce an EcoRI restriction site in the core of the putative CREB-1-binding site (CTTGCGTCA) using the following primers: 5 0 -TGGAATTCCGCTTCAGA GAGCGGAGAAGAGC-3 0 and 5 0 -CGGAATTCCAAGCT GGCTGGGCAGTTAGC-3 0 . Subsequently, a double PCR was performed using the above primers and the pGL3 vectorspecific primers, Rvprimer3 (5 0 -CTAGCAAAATAGGCTGT CCC-3 0 ) and GLprimer2 (5 0 -CTTTATGTTTTTGGCGTC TTCCA). The PCR products containing the EcoRI site were then subcloned in pGL3-Basic vector (Promega, Southampton, UK) to generate the pGL3 mutant (À1303) and (À444) cyclin D2 promoters, respectively. The plasmid encoding active PI3K (CD2p110), the kinase dead mutant (CD2p110KD) and the empty vector (pEF) constructs have been described previously (Brennan et al., 1997) . Expression plasmids for wild-type and the S133A mutant of CREB-1 mutants were purchased from Clontech.
Transfections and reporter assays
For transient expression, between 1.0 and 1.5 Â 10 7 Kit225 cells from a suspension culture were transfected by electroporation using a BioRad Genepulser II electroporator at 300 V and 950 mF at room temperature in 500 ml growth medium. Following electroporation, the cells were divided equally and transferred into 2 ml of fresh medium per sample and stimulated as indicated. The activity of the luciferase reporter plasmids was measured using a standard bioluminescence protocol (Mehl et al., 2001) .
Generation of nuclear extracts
Nuclear extracts were generated using a modification of a published protocol (Brennan and O'Neill, 1996) . Following the application of stimuli, as indicated, 5 Â 10 6 cells were harvested and placed on ice. They were centrifuged at 10 000 g for 1 min. Cells were washed in 1 ml of hypotonic buffer (10 mM HEPES (pH 7.9), 1.5 mM magnesium chloride, 10 mM potassium chloride, 10 mM PMSF) and centrifuged at 10 000 g for 1 min. Cells were lysed in 50 ml of hypotonic buffer with 0.1% Nonidet P40 and placed on ice for 5 min. The mixture was centrifuged for 5 min at 13 000 g. The supernatant was removed and the pellet was incubated with 15 ml of high-salt buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 25% glycerol, 0.5 mM PMSF) to release the transcription factors from the DNA. This was incubated on ice for 10 min and centrifuged for 5 min at 13 000 g. The supernatant was diluted in 75 ml of storage buffer (10 mM HEPES, pH 7.9, 50 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5 mM PMSF) and stored at À201C until further use.
Electrophoretic mobility shift assays
The protein from nuclear extracts was quantified by the Bradford method. Using a method described previously (Brennan and O'Neill, 1996) , equivalent quantities of nuclear protein (1-4 mg) were incubated with 32 P-radiolabelled probes, generated by T4 polynucleotide labelling. The probes corresponded to the sequence of the cyclin D2 promoter (Brooks et al., 1996) or a CREB-1 consensus sequence (Santa Cruz Biotechnology, sc-2504). For supershift assays, the nuclear extracts were preincubated for 30 min with 1 ml of antibodies for CREB1 or CREB2 from Santa Cruz Biotechnology: CREB-1 (C-21, sc-186); CREB-1 (24H4B, sc-7583); CREB-2 (C20, sc-186) and CREB-2 (C19, sc-7583). The binding reaction was performed in binding buffer (4% glycerol, 1 mM EDTA, 10 mM Tris, pH 7.5, 100 mM NaCl, 0.1 mg/ml bovine serum albumin, 5 mM dithiothreitol) with the addition of 2 ng of poly dIdC (Amersham) for 30 min at room temperature prior to separation of protein-DNA complexes using a 4% native acrylamide gel.
DNA-affinity precipitations
Nuclear extracts were generated as described above. The extracts were diluted with 20 volumes of salt-free buffer (50 mM Tris HCl pH 8, 0.25 mM EDTA, 10 mM NaF, 25% glycerol, 0.5 mM PMSF, 10 ml/ml Phosphatase Inhibitor Cocktail I (Sigma, P-2850) and Phosphatase Inhibitor Cocktail II (Sigma, P-5726), 1 mM NaVO 4 . Streptavidin-conjugated agarose beads (30 ml of 50% slurry) and biotinylated doublestranded oligonucleotide (1 mg) were added to the lysate, which was rotated for 1 h at 41C. The mixture was centrifuged at 12 000 g and the supernatant was removed. The beads were then washed in buffer three times and proteins were eluted from the beads by the addition of 2 Â gel sample buffer (0.1 M Tris buffer pH 6.8, 0.2 M dithiothreitol, 4% sodium dodecyle sulphate, 20% glycerol, 0.1% bromophenol blue). Proteins were separated by SDS-PAGE, transferred onto PVDF membranes and analysed using specific antibodies. The sequences of the oligonucleotides were: STAT -GTATTTCCCAGAAAAGGAA; NF-kB -AGTTGAGGGGACTTTCCCAGGC; CREB -AGAGAT TGCCTGACGTCAGAGAGCTAG; D2 -GGGAGGAGA GCTAACTGCCCAGCCAGCTTGCGTCACCGCTTCAGA GCGGA.
